Löfgren syndrome as secondary autoimmune disease in a patient with B-cell depletion following rituximab treatment

Clin Exp Rheumatol. 2018 May-Jun;36(3):515-516. Epub 2018 Mar 21.

Authors

Andreas Kronbichler¹, Anna K Luger², Lorin Loacker³, Alex Pizzini⁴, Judith Löffler-Ragg⁴, Ines Peschel³

Affiliations

¹ Department of Internal Medicine IV, Nephrology and Hypertension, Medical University Innsbruck, Austria. [email protected].
² Department of Radiology, Medical University Innsbruck, Austria.
³ Central Institute for Medical and Chemical Laboratory Diagnostics, Medical University Innsbruck, Austria.
⁴ Department of Internal Medicine II, Infectious Diseases, Immunology, Pneumology, Rheumatology, Medical University Innsbruck, Austria.

PMID: 29600945

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Ankle Joint
Arthritis / chemically induced*
Arthritis / drug therapy
Autoimmune Diseases / chemically induced*
Autoimmune Diseases / drug therapy
Dyspnea / chemically induced
Erythema Nodosum / chemically induced*
Erythema Nodosum / drug therapy
Female
Glucocorticoids / therapeutic use
Humans
Immunologic Factors / adverse effects*
Lymphadenopathy / chemically induced*
Lymphadenopathy / diagnostic imaging
Lymphadenopathy / drug therapy
Lymphocyte Depletion / methods
Methylprednisolone / therapeutic use
Middle Aged
Nephrosis, Lipoid / complications
Nephrosis, Lipoid / drug therapy*
Rituximab / adverse effects*
Syndrome
Tomography, X-Ray Computed

Substances

Glucocorticoids
Immunologic Factors
Rituximab
Methylprednisolone